Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.
There are four major models of drug release patterns. The first model is the slow zero-order release system. In this system, the drug is released at a constant rate, leading to a steady plasma concentration with minimal fluctuations. This is considered the ideal controlled delivery formulation as it minimizes peak-to-trough variations and helps maintain therapeutic levels over time. Zero-order release formulations are particularly beneficial for drugs with short half-lives, as they minimize the need for frequent dosing and enhance patient compliance.
The second model, slow first-order release, involves a gradual decrease in the rate of drug release over time. Unlike zero-order kinetics, the amount of drug released declines as the formulation advances through the gastrointestinal tract (GIT). Absorption efficiency decreases due to factors such as reduced intestinal surface area, increased viscosity, and diminished mixing. As a result, larger doses are needed to maintain therapeutic effects, making this system less favorable than zero-order release.
The third model combines an initial rapid loading dose with a slow zero-order release. This approach provides immediate drug action while sustaining therapeutic levels over time. However, a major drawback is the occurrence of transient peak concentrations, which may lead to toxicity or adverse effects. Repeated dosing can lead to undesirable fluctuations in plasma drug levels, necessitating adjustments in formulation design.
The fourth model features a rapid loading dose followed by slow first-order release. This design produces a burst effect, followed by a gradual decline in drug concentration. While this ensures initial efficacy, the declining release rate can lead to subtherapeutic levels over time, necessitating adjustments in dosage and frequency of administration.
To mitigate transient fluctuations, strategies such as decreasing the loading dose, increasing dosing intervals, or combining immediate-release formulations with controlled-release systems are employed. Each drug release model has advantages and limitations, requiring careful selection based on the drug’s pharmacokinetic properties and therapeutic goals.
Modified-release dosage forms control drug release to maintain therapeutic effects over an extended period.
If drug disposition follows first-order kinetics, the drug release rate constant is smaller than the absorption rate constant, and the released drug is completely absorbed, then the drug release can be categorized into four models.
The slow zero-order modified-release formulation is considered ideal because it maintains a constant drug release rate independent of drug concentration. With repeated dosing, it maintains steady plasma levels with minimal fluctuations.
Slow first-order release decreases in drug release over time, requiring dose adjustments or frequent dosing to remain effective.
Some formulations combine a rapid loading dose with a slow zero-order release, ensuring immediate therapeutic action with sustained effects. However, improper dosing intervals may risk drug accumulation and toxicity.
Others combine a rapid loading dose with slow first-order release, generating an initial burst followed by a gradual decline. This balances immediate efficacy with prolonged therapeutic action.
繁體中文
